Wire · regulatory
Inovio's Voceryq wins accelerated approval as first plasmid DNA immunotherapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
The US FDA granted accelerated approval to INOVIO Pharmaceuticals' Voceryq, the first plasmid DNA-based immunotherapy, for reducing surgical frequency in adults with recurrent respiratory papillomatosis. The approval sets a regulatory precedent for plasmid DNA medicines and is contingent on a confirmatory trial to verify clinical benefit.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
FDA's green light on plasmid DNA treatment opens a new pathway for DNA-based drugs in US biotech. You need to consider plasmid platforms as viable alternatives to viral or lipid carriers in clinical development.
◆ Coverage
9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics